Evidence map›Paper›PMID 39080245›Full record

ReviewCurrent topics in behavioral neurosciences2026

Neurobiological Correlates of Psychedelic Experiences and Psychedelic-Associated Adverse Effects.

Nathalie M Rieser, Timo T Schmidt, Katrin H Preller

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current topics in behavioral neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nathalie M RieserDepartment of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic Zurich and University of Zurich, Zurich, Switzerland. nathalie.rieser@bli.uzh.ch.
Timo T SchmidtNeurocomputation and Neuroimaging Unit, Department of Education and Psychology, Freie Universität, Berlin, Germany.
Katrin H PrellerDepartment of Adult Psychiatry and Psychotherapy, Psychiatric University Clinic Zurich and University of Zurich, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This chapter offers a comprehensive overview of our current understanding of the neural mechanisms underlying the effects of psychedelic drugs, with a primary focus on human neuroimaging studies. Whenever possible, we explore the neurobiological mechanisms that may underly acute and subacute adverse effects and describe hypotheses on how these results may inform on the pathophysiology of psychiatric illnesses. We delve into the general effects of psychedelics on EEG, fMRI, and PET measurements, drawing insights from experiments that have assessed their acute biological mechanisms. Additionally, we review the relatively limited literature exploring pre- to postdrug changes. Throughout this chapter, we explore the prevailing models of psychedelic drug actions, including the Cortico-Striato-Thalamo-Cortical (CSTC) feedback loop model, the entropic brain hypothesis, the REBUS principle (an extension of predictive brain theories), and the claustrum hypothesis. Finally, we delve into the neural correlates of distinct features of the psychedelic experience, encompassing visual effects, social and emotional impacts, and the phenomenon of ego dissolution. We offer speculations on how our current understanding of acute drug effects might relate to the rarely occurring long-term adverse effects. It is important to note that due to the scarcity of data, these speculations remain tentative.

Indexed as

BrainHallucinogensHumansHallucinogensAcute and long-term adverse effectsNeural mechanismsNeuroimagingPsychedelics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.